Los Angeles, California
PIH Health Good Samaritan Hospital
Los Angeles, CA
AMERICAN COLLEGE OF CARDIOLOGY
FIFTH ANNUAL SYMPOSIUM
Contemporary Management of
Cardiovascular Disease in Women
April 23, 2022
Omni Los Angeles Hotel
Los Angeles California
IMPORTANT CME CREDIT NOTICE
CME Certificates will be issued digitally after Speaker and Symposium Surveys are completed.
Surveys are accessible after logging in with the email address you submitted during registration.
Surveys will be accessible online the day of the symposium and for 3 weeks following. You must complete the
process by May 16, 2022 in order to receive your certificate. Certificates will be available online until TBD
and are printable directly from the website.
This Live activity, 5th Annual Contemporary Management of Cardiovascular Disease in Women, with a beginning date of April 23, 2022 has been reviewed and is acceptable for up to TBD Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity. (credit hours subject to change)
AMA: AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit™ toward the AMA Physician's Recognition Award.
AANPCP: The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AAFP Prescribed credit.
ANCC: According to the ANCC, the continuing education hours approved by the AAFP meet the ANCC-accredited CNE criteria.
AAPA: The American Academy of Physician Assistants accepts AAFP Prescribed credit for AAPA Category 1 CME credit.
This educational symposium will review the current epidemiology of cardiovascular disease in women and examine, in detail, specific cardiovascular issues, hormone therapy in menopause and valvular heart disease during pregnancy. Other cardiovascular diseases more common in women will also be examined, including pulmonary arterial hypertension, ischemia without obstructive CAD, effect of rheumatologic disorders and diabetes on ASCVD outcomes. Two major cardiovascular risk implicators, lipids and diet, will be discussed, including current data and guidelines. State of the art therapies for structural heart disease, including aortic and mitral valves will be included, with an emphasis on gender-specific outcomes. The newest data on direct oral anticoagulants and reversal agents will be included, as well as women-specific considerations in the management of heart failure. The concluding session will provide case-based vignettes illustrating clinical application of the latest cardiovascular trials.
The objective of this symposium is to educate healthcare providers on gender-specific approaches in prevention, diagnosis, and treatment of women with a broad range of cardiovascular diseases.
At the conclusion of this activity, the participants should be able to:
- Be aware of the current epidemiology of cardiovascular disease in women
- Discuss differences in microvascular disease trials
- Discuss gender specific disorders in pulmonary arterial hypertension
- Understand the current studies and management of women with ischemia without obstructive CAD
- Review dyslipidemia therapies and specific outcomes in women
- Be aware of the gender specific outcomes between TAVR and SAVR
- Explore therapies for TMVR MitraClip
- Understand diabetes effects in cardiovascular disease in women
- Understand the role of PFO closure in cyptogenic stroke
- Recognize the most current dietary interventions to prevent cardiovascular disease
- Discuss the diagnosis and management of valvular heart disease in pregnancy
- Examine the changing indications for NOAC therapy and potential complications
- Compare the pharmacologic and cardiac device considerations for heart failure in women
- Be able to recognize a wide range of cardiovascular disorders affecting women by examining complete case studies, including presentations, work-ups, and therapies
Heart disease is the leading cause of death in women in the U.S. and accounts for more deaths each year than all of the other causes combined. In women of racial or ethnic minority the rates of death are even higher. One in three women will die of some form of heart or vascular disease. However, only one-third of women are aware of this statistic and only half would call 911 if they had symptoms of a heart attack. Compared to men, women are less likely to receive standard of care of treatment for chest pain, less likely to be referred to a cardiologist, and less likely to be admitted to the hospital. It is our mission to educate healthcare providers about the impact of cardiovascular disease on women and empower them to be advocates for women's cardiovascular health.
This program has been designed to provide primary care physicians, internists, cardiologists, nurse practitioners, physician assistants, nurses, pharmacists and other healthcare providers with the necessary information to increase knowledge and awareness of cardiovascular disease in women with the goal of improving patient care.
CULTURAL AND LINGUISTIC COMPENTENCY
This activity is in compliance with California Assembly Bill 1195 which requires continuing medical education activities with patient care components to include curriculum in the subjects of cultural and linguistic competency. Cultural competency is defined as a set of integrated attitudes, knowledge, and skills that enables health care professionals or organizations to care effectively for patients from diverse cultures, groups, and communities. Linguistic competency is defined as the ability of a physician or surgeon to provide patients who do not speak English or who have limited ability to speak English, direct communication in the patientís primary language. Cultural and linguistic competency was incorporated into the planning of this activity.
It is our policy to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. All conflicts of interest will be resolved prior to an educational activity being delivered to learners through one of the following mechanisms 1) altering the financial relationship with the commercial interest, 2) altering the individualís control over CME content about the products or services of the commercial interest, and/or 3) validating the activity content through independent peer review. All persons are also required to disclose any discussions of off label/unapproved uses of drugs or devices. Persons who refuse or fail to disclose will be disqualified from participating in the CME activity.